| 摘要 |
The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effectiv e viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides genera l and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, su ch as a human. These findings can be applied to other respiratory viruses.</SDO AB> |
